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1607-551X/Copyright ª 2014, KaohsiuAbstract This study was to elucidate longitudinally quantitative changes of hepatitis B virus
(HBV) surface antigen (HBsAg) and HBV DNA in elder HBsAg carriers in a community. Among
1002 residents screened for HBsAg in 2005, 405 responded to this follow-up study in 2010.
Fifty-nine (14.6%) were HBsAg carriers in 2005; HBsAg quantification and HBV DNA were
measured. HBsAg quantification (cutoff 1600 IU/mL) and HBV DNA (cutoff 2000 IU/mL) were
combined to stratify the participants between two screens. A total of 30 men and 29 women
with a mean age of 63.9  7.9 years were enrolled. Quantitative levels of HBsAg and HBV DNA
were significantly correlated in 2005 (r Z 0.509, p < 0.001) and 2010 (r Z 0.777, p < 0.001).
Concentrations of HBsAg (IU/mL) significantly decreased from 2.2  1.0 log in 2005 to 1.7  1.5
log in 2010 (p < 0.001). The level of HBsAg was decreased in 48 (81.4%) individuals and HBsAg
was undetectable in eight (13.6%). The annual incidence of HBsAg clearance was 2.7%. These
59 HBsAg carriers in 2005 were divided into four groups: low HBsAg low HBV DNA (nZ 32), high
HBsAg low HBV DNA (n Z 5), low HBsAg high HBV DNA (n Z 12) and high HBsAg high HBV DNA
(nZ 10). All 32 individuals in the low HBsAg low HBV DNA group were still in that group in 2010,
whereas only two of the high HBsAg high HBV DNA group became inactive. As with a younger
cohort in hospital, HBsAg quantification was still well correlated with HBV DNA in elderly HBsAgeclare no conflicts of interest.
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Quantitative HBsAg and HBV DNA 103carriers in the community. Lower levels of both HBsAg and HBV DNA might represent an inac-
tive HBV infection.
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Chronic hepatitis B virus (HBV) infection affects 350e400
million people worldwide and is associated with 1 million
mortalities every year [1]. The purpose of treatment for
patients with chronic HBV infection is to decrease the pro-
gression of liver disease to cirrhosis and hepatocellular car-
cinoma in order to improve the rate of survival. Currently,
anti-HBV therapies can include long-term treatment with
nucleos(t)ide analogs to maintain constant inhibition of viral
replication and a limited treatment period where interferon
can be used to induce a sustained immune response [2,3].
Quantification of HBV DNA is widely used as the indicator of
viral replication to assess the type of treatment that is
appropriate [4e6]. However, the high expense of this assay
has limited its utility clinically. The serum concentration of
HBV surface antigen (HBsAg) is proposed to reflect the
amount of covalently closed circular DNA (cccDNA) in the
liver, where it acts as template for the transcription of viral
genes [7]. Recently, several studies have reported that serum
HBsAg levelsmay be a good indicator in predicting a patient’s
response to interferon-based therapy, andwas shown tohave
good association with serum HBV DNA levels [8e11].
The nature history of chronic HBV infection has been
well illustrated with four phases: immune tolerant phase,
immune clearance phase, residual inactive phase, and
reactive immune clearance phase [12]. Most studies were
conducted with younger HBV carriers to evaluate the as-
sociation of HBV infection and treatment. By contrast,
older HBV carriers have been studied less, especially in
hospitals. However, the association between virus infection
and host might be varied in different aged cohorts [13].
In the past decade, some immunoassays have been
developed to measure the HBsAg titer quantitatively
[14,15]. In addition, these tests are inexpensive and the
detection process is much more convenient. The HBsAg
quantification test has been applied in chronic hepatitis B
patients in the hospital to evaluate the severity of liver
disease and clinical outcome [16e19]; however, the test
has never been used for studying older HBV carriers in
community screening. Therefore, we have conducted this
follow-up community-based study to elucidate the longi-
tudinally quantitative changes in HBsAg and HBV DNA levels
in elder HBsAg carriers.Materials and methods
Study participants
Tzukuan township is located in southern Taiwan with a total
population of about 40,000, and has been reported to be anHBV-endemic area, with an estimated HBsAg-positive
prevalence of 12.6% [20]. In 1997, 2909 residents (30.6%
of the total population within the age group of 45 years and
older), were screened for HBsAg [21]. In 2005, a follow-up
study was conducted; however, only 1002 participants
responded [22e24]. In 2010, a follow-up community
screening was again performed with the cohort from 2005.
Using invitation methods such as phone calls and mail, 405
(40.4%) residents were enrolled, 59 of whom were HBsAg
carriers in 2005. Serum quantitative HBsAg level and HBV
DNA levels were further measured and analyzed using the
carriers’ stored sera (collected both in 2005 and 2010). To
distinguish active HBV infection from inactive reaction,
cutoff values of 1600 IU/mL and 2000 IU/mL were set for
HBsAg and HBV DNA, respectively [3,22]. These two cutoff
points were also used as grouping indices. According to the
data collected in 2005, the 59 HBsAg carriers were divided
into four groups: low HBsAg low HBV DNA (LsLD group), high
HBsAg low HBV DNA (HsLD), low HBsAg high HBV DNA
(LsHD), and high HBsAg high HBV DNA (HsHD). This study
was approved by the Institutional Review Board of Chang
Gung Memorial Hospital, Kaohsiung, Taiwan.
Quantitative HBsAg assay
The quantification of HBsAg was performed with Architect
qHBsAg (Abbott Diagnostic, Wiesbaden, Germany),
following the manufacturer’s instructions [25]. The sensi-
tivity of the Architect assay was 0.05e250 IU/mL. Samples
with HBsAg titer >250 IU/mL were diluted from 1:500 to
1:1000 to bring the reading within the range of the cali-
bration curve.
HBV DNA assay
The levels of HBV DNA were quantified using the COBAS
AmpliPrep-COBAS TaqMan HBV test (CAP-CTM; Roche Mo-
lecular Systems Inc., Branchburg, NJ, USA), with a lower
detection limit of 12 IU/mL (70 copies/mL). Dilution was
performed if the HBV DNA levels was >106 copies/L.
Statistical analysis
The continuous variables in this study were expressed as
mean  standard deviation. The paired t test was used to
determine the significances of the continuous dependent
variables. The Chi-square test was used to verify the dif-
ferences between the categorical factors. Linear regression
analysis was used to assess the linear associations between
serum HBsAg and HBV DNA levels (HBsAg and HBsAg levels
as well as HBV DNA and HBV DNA levels were analyzed in
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performed using SPSS software (version 15.0; SPSS Inc.,
Chicago, IL, USA). The statistical significance was set at
p < 0.05.Results
A total of 30 men and 29 women were enrolled into this
study. The mean age of the participants was 63.9  7.9
years. Table 1 shows the longitudinal changes of clinical
characteristics among the 59 participants at the initial and
follow-up screening. Mean serum level of aspartate
aminotransferase was reduced from 31.6  17.9 IU/mL to
29.6  13.9 IU/mL (p Z 0.004), and the alanine amino-
transferase level was reduced from 33.8  30.5 IU/mL to
25.2  15.2 IU/mL (p Z 0.008), from 2005 to 2010,
respectively. Concentrations of HBsAg (IU/mL) and HBV
DNA (IU/mL) were also significantly decreased from
2.2  1.0 log to 1.7  1.5 log (p < 0.001) and from 7.6  3.2
log to 5.5  2.7 log (p < 0.001), in 2005 and 2010,
respectively. Forty-eight (81.4%) individuals were shown to
have decreased concentrations of HBsAg, compared to their
first screening, and eight (13.6%) individuals were cleared
of HBsAg. Likewise, 45 (76.3%) participants were shown to
have decreased levels of HBV DNA and six (10.2%) partici-
pants were clear of HBV DNA. The annual incidences of
HBsAg and HBV DNA clearance were estimated to be 2.7%
and 2.0%, respectively. Serum levels of HBsAg in 2005
correlated significantly with that determined in 2010
(r Z 0.779, p < 0.001; Fig. 1A). Similarly, serum levels of
HBV DNA in 2005 also showed significant correlation with
those obtained in 2010 (r Z 0.596, p < 0.001; Fig. 1B).
Regarding the association between the two markers, con-
centrations of HBsAg and HBV DNA were significantlyTable 1 Longitudinal change in clinical characteristics among
follow-up screens.
First screen
in 2005
Foll
Age (y) 63.9  7.9 68  7.9
Male 30 (50.8) 30 (50.8
AST (IU/mL) 31.6  17.9 29.6  1
ALT (IU/mL) 33.8  30.5 25.2  1
qHBsAg (IU/mL) 960.4  7.7 (1.9e6167.1) 578.5 
Log qHBsAg (IU/mL) 2.2  1.0 1.7  1.
qHBsAg < 1600 IU/mL 44 (74.6) 50 (84.7
qHBsAg <0.5 (IU/mL)a 0 8 (13.6)
HBeAg positive 2 (3.4)b 1 (1.7)
HBV DNA (IU/mL), 637,456.5  5765
(59e356,500,000)
18,759.9
(<12e33
Log HBV DNA (IU/mL) 3.2  1.3 2.7  1.
HBV DNA<2000 (IU/mL) 37 (62.7) 38 (64.4
HBV DNA <12 (IU/mL)a 0 6 (10.2)
Data are presented as n (%), mean  SD, or mean  SD (range).
* Comparison with paired-sample t test.
HBeAg Z hepatitis B e antigen; qHBsAg Z quantitative hepatitis B su
a Lowest limit of detectable qHBsAg and HBDNA level in our institu
b One patient became HBeAg negative in 2010.correlated in 2005 (rZ 0.509, p < 0.001; Fig. 2A) as well as
in 2010 (r Z 0.777, p < 0.001; Fig. 2B).
At the follow-up screening, 11 (18.6%) and 48 (81.4%)
individuals showed increased and decreased HBsAg levels,
respectively. For HBV DNA, 14 (23.7%) and 45 (76.3%) par-
ticipants showed increased and decreased levels of HBV
DNA, respectively. Forty (67.8%) participants had the
concordance of decreasing HBsAg and HBV DNA, whereas six
(10.2%) participants showed an increase in both markers.
The combination of HBsAg quantification (cutoff 1600 IU/
mL) and HBV DNA (cutoff 2000 IU/mL) was used as grouping
index. All 32 participants who were classified into the LsLD
group in 2005 were still in the same group in 2010. The
HBsAg levels of all five HsLD individuals were still >1600 IU/
mL. Three of them remained in the HsLD group and two of
them became HsHD in 2010. Four (33.3%) individuals in the
LsHD group and two (20%) of the HsHD group became LsLD
inactive in the follow-up screening in 2010 (Table 2).
Discussion
The reduction of serum HBsAg concentration has been
proposed to reflect the reduction of cccDNA in the liver [7],
which might represent improved immune control over viral
replication [26]. Therefore, serum HBsAg level can be used
to monitor active HBV infection. In the clinical field, HBsAg
has long served as the qualitative diagnostic test for HBV
infection; however, new assay techniques have been
developed to measure the HBsAg level quantitatively
[14,15]. As a diagnostic marker of HBV infection, quantifi-
cation of serum HBV DNA level is currently adopted for
selecting candidates for therapy, monitoring response to
therapy, and detecting the occurrence of drug resistance
[2,3]. Previous studies have reported that serum HBsAg
levels showed a good correlation with HBV DNA and can be59 positive HBsAg quantification participants at the first and
ow-up screen
in 2010
Difference p*
)
3.9 4.7  15.8 0.004
5.2 4.4  16.1 0.008
7.7 (<0.5e637.7) 381.9  979.1 (162.7e634.8) 0.004
5 0.5  0.9 <0.001
)
 1578
6,000)
618,696.6  11,290.1
(583,012e1,837,400)
<0.001
5 0.5  1.3 <0.001
)
rface antigen.
te.
Figure 1. Significant correlation of (A) log hepatitis B virus
(HBV) surface antigen quantification in 2005 with log HBV
surface antigen quantification in 2010, and (B) log HBV DNA in
2005 with log HBV DNA in 2010.
Figure 2. Significant correlation of (A) log hepatitis B virus
(HBV) surface antigen quantification with log HBV DNA in 2005,
and (B) log HBV surface antigen quantification with log HBV
DNA in 2010.
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therapy [8e11]. Compared to younger cohorts in hospital-
based studies, we demonstrated a longitudinally good as-
sociation between HBsAg quantification and HBV DNA in
elderly aged cohort in the community. Quantitative mea-
surements of HBsAg and HBV DNA showed a significant
correlation in 2005 (rZ 0.509, p < 0.001) as well as in 2010
(r Z 0.777, p < 0.001) in our aged cohort. The association
between the two markers in our aged participants became
more significant in the follow-up visit, which was 6 years
after the initial screening. The concordant lower levels of
serum HBsAg and HBV DNA in most individuals at the follow-
up might explain this phenomenon. Serum levels of HBsAg
in the two screens were significantly correlated (rZ 0.779,p < 0.001). In addition, HBV DNA also showed a significant
correlation (r Z 0.596, p < 0.001) between the two
screens. Thus, we concluded that HBsAg and HBV DNA are
both stable markers in screening for aged HBV carriers. In
the past, qualitative HBsAg assay was used as the first-line
screening tool in the community. The patients who showed
doubtable active HBV infections were transferred to the
hospital for further detection of their viremia level. Serum
level of HBV viremia can be used to represent the activity
of HBV replication accurately. However, the HBV DNA level
has very limited clinical use in community screening
because HBV DNA assays are more expensive and require
well-trained technicians. Our study demonstrated that
HBsAg quantification showed a longitudinally good associ-
ation with HBV DNA in community-based elderly cohort.
The less expansive, fully automated, and high throughout
quantitative HBsAg assays [27] might be suitable as the
first-line screening tool to offer quantitative diagnosis of
Table 2 Grouping of 59 positive HBsAg quantification
participants according to combination of HBsAg (cutoff
1600 IU/mL) and HBV DNA (cutoff 2000 IU/mL) in 2005 and
2010.
In 2005
LsLD
group, n
HsLD
group, n
LsHD
group, n
HsHD
group, n
In 2010
LsLD group 32 0 4 2
HsLD group 0 3 6 3
LsHD group 0 0 0 0
HsHD group 0 2 2 5
HsHD Z qHBsAg 1600 IU/mL and HBV DNA 2000 IU/mL;
HsLD Z qHBsAg 1600 IU/mL and HBV DNA <2000 IU/mL;
LsHD Z qHBsAg<1600 IU/mL and HBV DNA 2000 IU/mL;
LsLD Z qHBsAg <1600 IU/mL and HBV DNA <2000 IU/mL;
qHBsAg Z quantitative hepatitis B surface antigen.
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Taiwan.
In the natural history of HBV infection, HBV replication
becomes inactive gradually in the elderly aged cohort, and
this period is defined as the inactive phase [12,28]. In our
study participants, the aged cohort’s viremia levels (rep-
resented in log scale) decreased significantly from the
initial screening in 2005 to the follow-up in 2010. Further-
more, 45 (76.3%) participants showed significantly
decreased serum HBV DNA levels and six (10.2%) partici-
pants showed a cleared HBV DNA, while no antiviral treat-
ment was given to any of the participants during the period
between the screenings (2005e2010). The annual incidence
of viremia clearance was 2.0% (95% confidence interval,
2.02e3.07). In addition to decreased viremia levels, im-
provements were also observed in the individuals’ liver
biochemical markers, which include AST and ALT levels.
This reduction in biochemical markers might indirectly
reflect the improvement of liver inflammation. In regard to
HBsAg quantification, the REVEAL-HBV study group has
shown that the estimated annual HBsAg seroclearance rate
in the communities in Taiwan was about 2.26% [29]. In
another large-scaled hospital based study in Taiwan, Tai
et al. [30] reported that the estimated annual HBsAg
seroclearance rate, for patients older than 50 years, was
around 1.05e1.61%. This suggests that HBsAg seroclearance
is the main reason of decreased HBsAg prevalence in aged
populations. Our study findings are also in support of this
result, where 48 (81.4%) individuals showed decreased
concentrations of HBsAg and eight individuals (13.6%)
cleared their HBsAg. The annual incidence of HBsAg clear-
ance in the elderly aged population is 2.7% (95% confidence
interval, 2.1e3.3), which was higher than previous Taiwan
studies [29,30]. The HBsAg clearance rate raised with the
age increase was demonstrated [12]. Although all of our
enrolled patients did not receive antiviral treatment, their
older age (mean: 68  7.9 years) might explain the higher
clearance rate in the current study. Among eight HBsAg loss
participants, six also lost their viremia concordantly at the
follow-up. The other two participants had low HBV DNA
titer (1650 IU/mL and 50 IU/mL), which might be atransient discordance. The longitudinal change of serum
HBsAg levels observed in this study showed a good associ-
ation with HBV DNA count, where an excellent concordance
(46/59, 77.9%) of the two markers was observed. Forty
participants showed concordantly decreased concentra-
tions of the HBsAg and HBV DNA at the follow-up visit, while
only six participants had concordant increase. Further-
more, 28 participants showed concordant decrease of
HBsAg quantification and HBV DNA of more than one log
scale reduction, which suggests that higher levels of im-
mune control were exhibited in these individuals [31].
Previous studies reported that 1600 IU/mL for HBsAg
quantification and 2000 IU/mL for HBV DNA can be used as
cutoff points to distinguish between active HBV infection
and inactive infection [3,22]. A combination of the two
cutoffs of HBsAg quantification and HBV DNA was used in
this study as the stratifying grouping index for the partici-
pants in 2005 to monitor the longitudinal change. A total of
59 participants were divided into four groups that include
32 in the LsLD, five in the HsLD, 12 in the LsHD, and 10 in
the HsHD group. All 32 (100%) individuals in the LsLD group
remained in the same group in 2010, while five (50%) par-
ticipants of the HsHD group remained active. All HsLD cases
still retained high levels of HBsAg during the follow-up;
however, two (40%) individuals had shown increased HBV
DNA levels. Finally, 10 (83.3%) of LsHD cases became inac-
tive viremia in 2010. Additionally, all 59 individuals were
diagnosed as parenchymal liver disease or fatty liver by the
ultrasound in 2005, and only two cases became liver
cirrhosis in 2010; both were persistently in the HsHD group.
Therefore, we concluded that a combined serum levels of
HBsAg quantification <1600 IU/mL and HBV DNA <2000 IU/
mL can be a reliable index of inactive HBV infection.
Meanwhile, a reduction in quantitative HBsAg can be used
to predict HBV infection inactivity better than HBV DNA;
however, additional studies are still required to verify this
result.
There were some limitations in our study. In this follow-
up community study, as only HBsAg positive individuals
were recruited, the small case number was a limitation. In
addition, although increased body mass index with hepatic
steatosis contributed to HBsAg clearance has been reported
[31], the body mass index levels were not recorded at the
enrollment. A previous study reported that HBV genotype B
or C was not associated with HBsAg clearance HBeAg-
negative patients [19], we are unable to provide informa-
tion about HBV genotype in the community because the
shortage of stored sera in 2005.
In conclusion, as for a young cohort in hospital, HBsAg
quantification was demonstrated to be significantly asso-
ciated with HBV DNA in older individuals in the community.
In HBV-endemic areas, using quantitative HBsAg assays as
the first-line screening tool can become a more economi-
cally solution in detecting active HBV infection than qual-
itative HBsAg assays combined with quantitative HBV DNA
tests. In addition, the annual incidences of HBsAg and HBV
DNA clearance in our aged cohort were estimated as 2.7%
and 2.0%, respectively. Finally, the combination of lower
levels of combined HBsAg quantification (<1600 IU/mL) and
HBV DNA (<2000 IU/mL) might be a reliable index in
determining inactive HBV infection in the community.
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